Lee, Po-HsinPo-HsinLeeCHUN-JU CHIANGTseng, Jeng-SenJeng-SenTsengZheng, Zhe-RongZhe-RongZhengChen, Kun-ChiehKun-ChiehChenChu, Cheng-HsiangCheng-HsiangChuHuang, Yen-HsiangYen-HsiangHuangHsu, Kuo-HsuanKuo-HsuanHsuWEN-CHUNG LEEYang, Tsung-YingTsung-YingYangLiu, Tsang-WuTsang-WuLiuHsia, Jiun-YiJiun-YiHsiaChang, Gee-ChenGee-ChenChang2023-04-122023-04-1220232234-943Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/630167For patients with T2aN0 stage IB lung adenocarcinoma, benefits of adjuvant chemotherapy remain controversial. Here, we aimed to evaluate such benefits.enT2aN0; adjuvant chemotherapy; early lung cancer; lung adenocarcinoma; stage IBAdjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinomajournal article10.3389/fonc.2023.1096683369259282-s2.0-85150217231WOS:000949016500001https://api.elsevier.com/content/abstract/scopus_id/85150217231